GCM
KYMR icon

Ghisallo Capital Management’s Kymera Therapeutics KYMR Stock Holding History

Ghisallo Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,000
Closed -$436K – 242
2025
Q2 		$436K Buy
+10,000
New +$344K 0.01% 178
2023
Q3 		– Sell
-50,000
Closed -$1.15M – 147
2023
Q2 		$1.15M Buy
+50,000
New +$1.43M 0.14% 87

Other funds holding KYMR

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Ghisallo Capital Management's KYMR Position: Q3 2025 in Review

Ghisallo Capital Management sold out of Kymera Therapeutics (KYMR) in Q3 2025, closing a stake of 10,000 shares — an estimated $436K sold.

Ghisallo Capital Management first reported a position in KYMR in Q2 2023 and held it in 2 quarters. The position peaked at $1.15M in Q2 2023. 210 funds tracked by Wall St. Rank hold KYMR as of Q3 2025.

  • Ghisallo Capital Management reported no remaining Kymera Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Ghisallo Capital Management sold 10,000 Kymera Therapeutics shares in Q3 2025, an estimated $436K.
  • Ghisallo Capital Management first reported a position in Kymera Therapeutics in Q2 2023 and held it in 2 quarters.
  • Ghisallo Capital Management's Kymera Therapeutics position peaked at $1.15M in Q2 2023.
  • 210 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2025.

Based on Ghisallo Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.